| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Gallic aldehyde targets the herpes simplex virus type 1 (HSV-1). As a potent antiviral agent, it inhibits HSV-1 replication. Its mechanism of action may involve inhibition of viral entry, replication, or assembly, but the exact molecular target is not fully detailed in the provided sources. It is an HSV-1 inhibitor isolated from Geum japonicum.
|
|---|---|
| ln Vitro |
In vitro, Gallic aldehyde shows potent antiviral activity against HSV-1. Its activity is typically assessed in antiviral assays measuring the inhibition of viral replication in infected cells. The compound's effectiveness against HSV-1 is confirmed by its ability to reduce viral titers or cytopathic effects.
|
| ln Vivo |
In vivo studies for Gallic aldehyde are not extensively detailed in the provided literature. As a potent antiviral compound, it has potential for in vivo applications in the treatment of HSV-1 infections. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile.
|
| Enzyme Assay |
For non-cellular enzyme/receptor binding studies, Gallic aldehyde's antiviral activity can be evaluated in assays targeting HSV-1 enzymes, such as viral DNA polymerase or thymidine kinase. However, specific biochemical targets are not detailed in the provided sources. Its activity is typically confirmed in cell-based antiviral assays.
|
| Cell Assay |
For in vitro cellular experiments, cells susceptible to HSV-1 infection (e.g., Vero cells) are cultured and infected with the virus. The cells are treated with Gallic aldehyde at various concentrations, and viral replication is assessed by measuring viral titers, plaque formation, or viral DNA levels. Cytotoxicity is assessed in parallel using standard cell viability assays.
|
| Animal Protocol |
In vivo animal studies for Gallic aldehyde are not extensively documented. However, its potential for in vivo applications in the treatment of HSV-1 infections is suggested by its potent in vitro activity. Studies in animal models of HSV-1 infection, such as mouse models of herpes, would be needed to evaluate its in vivo efficacy. The compound could be administered topically or systemically.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Gallic aldehyde are not extensively detailed in the provided sources. It has a molecular weight of 154.12 and is readily soluble in polar organic solvents like DMSO and methanol, but has limited solubility in water. It should be stored at 2-8°C. Comprehensive pharmacokinetic studies are needed to fully characterize its ADME properties.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Gallic aldehyde is not explicitly detailed in the provided sources. As a naturally occurring compound, it may have a favorable safety profile, but standard laboratory safety precautions should be followed when handling it. It is intended for research use only and is not for human therapeutic applications.
|
| References | |
| Additional Infomation |
According to reports, 3,4,5-trihydroxybenzaldehyde is found in lentils, Japanese water hyacinth, and other organisms for which data is available.
Gallic aldehyde is a phenolic aldehyde with a molecular formula of C7H6O4 and a molecular weight of 154.12. It is isolated from Geum japonicum and shows potent antiviral activity against HSV-1. This research compound is for laboratory use only and has not been approved for clinical applications. |
| Molecular Formula |
C7H6O4
|
|---|---|
| Molecular Weight |
154.12
|
| Exact Mass |
154.026
|
| CAS # |
13677-79-7
|
| PubChem CID |
83651
|
| Appearance |
White to light brown solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
355.3±37.0 °C at 760 mmHg
|
| Melting Point |
211-213°C
|
| Flash Point |
182.9±23.0 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.734
|
| LogP |
0.9
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
135
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RGZHEOWNTDJLAQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H6O4/c8-3-4-1-5(9)7(11)6(10)2-4/h1-3,9-11H
|
| Chemical Name |
3,4,5-trihydroxybenzaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (811.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (13.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (13.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4885 mL | 32.4423 mL | 64.8845 mL | |
| 5 mM | 1.2977 mL | 6.4885 mL | 12.9769 mL | |
| 10 mM | 0.6488 mL | 3.2442 mL | 6.4885 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
